margetuximab   Click here for help

GtoPdb Ligand ID: 8686

Synonyms: Margenza® | margetuximab-cmkb | MGAH-22
Approved drug
margetuximab is an approved drug (FDA (2020))
Compound class: Antibody
Comment: Margetuximab is a chimeric monoclonal antibody targeting epidermal growth factor receptor 2 (ERBB2).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence search of patented sequences reveals a 100% match between the heavy chain variable domain of margetuximab and SEQ ID NO: 13 from patent US8802093 B2, and antibody clone ch4D5-FcMT3 [2]. Although the patent describes performing Biacore assays to determine antibody-target (ERBB2) affinity, a KD value is not provided.
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
erb-b2 receptor tyrosine kinase 2 Primary target of this compound Hs Antibody Binding - - - 2
⤷ [2]